查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984210

肿瘤精准医疗市场：依产品类型、技术、生物标记类型、癌症类型和最终用户划分－2026年至2032年全球市场预测

Oncology Precision Medicine Market by Product Type, Technology, Biomarker Type, Cancer Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肿瘤精准医疗市场价值将达到 28.1 亿美元，到 2026 年将成长至 30 亿美元，到 2032 年将达到 44.2 亿美元，复合年增长率为 6.68%。

主要市场统计数据
基准年 2025 28.1亿美元
预计年份：2026年 30亿美元
预测年份 2032 44.2亿美元
复合年增长率 (%) 6.68%

本策略性导论探讨了诊断技术的创新、治疗方法的进步和数据整合如何共同作用，重新定义精准肿瘤学的临床路径和商业性方法。

精准肿瘤学正处于转折点，治疗方法、诊断和数据分析领域的进步正在融合，重塑临床决策和商业策略。免疫疗法、标靶治疗和分子诊断领域的最新创新，正促使人们将关注点从统一的治疗方案转向更加分层的患者诊疗路径，这就需要建立新的循证医学模型，并加强包括临床医生、监管机构和支付方在内的各相关人员之间的合作。

治疗方法的进步、诊断复杂性的增加以及支付方期望的改变，迫使癌症治疗的开发和实施的整个过程采用综合性的策略方法。

精准肿瘤学领域正经历一场变革，其驱动力包括技术成熟、监管进步以及相关人员期望的转变。 CAR-T细胞疗法和查核点抑制剂等免疫疗法正从新兴疗法发展成为治疗流程中不可或缺的组成部分，重新​​定义了骨髓恶性肿瘤和某些固体癌的治疗结果。同时，以单株抗体和小分子抑制剂形式给药的标靶治疗，也透过标靶检验和改进抗药性管理策略，不断拓展其治疗范围。

评估新关税政策对精准肿瘤学供应链、检查室运作和临床专案韧性的营运和策略影响。

2025年新关税政策的实施将进一步增加整个精准肿瘤学生态系统的运作复杂性，影响试剂、仪器组件和生物製药生产投入品的供应链。单株抗体、细胞治疗材料和定序平台的生产商将面临某些进口原材料和仪器组件接收成本增加的问题，迫使他们重新评估筹资策略和库存管理实践。

主导细分市场，明确治疗领域、癌症类型、诊断技术、生物标记分类和最终用户采用率，从而指南优先排序。

基于细分市场的细緻观点能够清楚阐明价值创造点和营运重点所在。就治疗方法类型而言，荷尔蒙疗法仍然是多种治疗途径的基础；免疫疗法涵盖细胞疗法，例如CAR-T细胞疗法和全身性查核点抑制剂；标靶治疗则包括单株抗体和小分子抑制剂。每种疗法类别都有其独特的研发、生产和商业化考量，这些都会影响跨部门规划。

区域比较分析突显了主要地区在采用率、报销制度和基础设施方面的差异如何推动了差异化的精准肿瘤学策略。

区域趋势影响整个精准肿瘤学生态系统的应用模式和策略重点。在美洲，创新中心和完善的临床基础设施支持先进治疗方法和全面基因组分析的快速应用。然而，支付方环境和报销途径的差异，使得针对不同国家和地区市场制定有针对性的证据计划和支付方沟通策略成为必要。

关键参与者之间的策略联盟、平台投资和垂直整合如何重塑精准肿瘤学领域的竞争动态和价值创造。

治疗、诊断和综合服务领域的主要企业正透过策略联盟、平台投资和垂直整合重塑竞争动态。生物製药公司正日益与诊断开发公司合作，共同设计伴随检测和并行证据生成项目，以支持监管申报和与支付方的沟通。诊断实验室和仪器製造商正投资于自动化和数位化报告，以扩大高度复杂检测的规模，同时提高重复性和反应速度。

为领导者提供实际有效的建议，以整合诊断开发、供应弹性和证据生成，从而加速采用和获得支付方的认可。

产业领导者应采取果断措施，协调临床开发、诊断策略和商业性部署，确保治疗方法的进步能持续造福患者，并带来永续的商业成果。优先事项包括在治疗方法生命週期的早期阶段就纳入伴随诊断的开发，以降低监管风险，并为支付方和医疗服务提供者提供更清晰的价值提案。领导者应透过供应商多元化、尽可能采用双重采购以及对区域製造能力进行策略性投资来增强供应链的韧性。

结合专家访谈、监管和临床证据审查以及情境分析，采用稳健的多方面调查方法，提供实用见解。

本综述的背景研究采用多种方法，旨在捕捉精准肿瘤学整体的技术、临床、监管和营运趋势。透过对临床意见领袖、检查室管理人员和供应链高管进行访谈，我们获得了关于检测实施和治疗方法开发中实际操作情况的定性见解。我们将这些一线观点与官方监管决策、同行评审的临床文献和技术产品文件进行交叉比对，以确保其符合当前的临床和技术标准。

强调诊断、治疗开发和弹性运作的整合，并整合策略结论，以确保永续的患者疗效和商业性成功。

总之，精准肿瘤学正迈入一个以整合诊断、治疗方法特异性策略和对真实世界数据日益增长的需求为特征的新时代。免疫疗法、标靶治疗和先进诊断平台的相互作用正迫使相关人员重新思考研发模式、商业模式和营运基础设施。那些能够将伴随诊断研发与治疗方案同步、建立稳健的供应链网络并投资于可互通数据系统的机构，将更有能力将科学进步转化为持续的临床获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肿瘤精准医疗市场：依产品类型划分

  • 诊断
  • 治疗
    • 荷尔蒙疗法
    • 细胞和基因治疗
    • 免疫疗法
  • 抑制剂
  • 单株抗体

第九章 肿瘤精准医疗市场：依技术划分

  • FISH
  • IHC
  • 次世代定序
  • PCR

第十章：依生物标记类型分類的肿瘤精准医疗市场

  • 表观遗传学检测
  • 基因检测
  • 蛋白质检测

第十一章：以癌症类型分類的肿瘤精准医疗市场

  • 乳癌
  • 结肠癌
  • 肺癌
  • 恶性黑色素瘤
  • 摄护腺癌

第十二章 肿瘤精准医疗市场：依最终用户划分

  • 门诊部
  • 诊所
  • 诊断检查室
  • 医院

第十三章 肿瘤精准医疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肿瘤精准医疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 肿瘤精准医疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肿瘤精准医疗市场

第十七章：中国肿瘤精准医疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • BJ Madan & Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • Genome Medical boasts
  • GSK PLC
  • IQVIA Inc.
  • Laboratory Corporation Of America Holding
  • llumina, Inc.
  • Merck KGaA
  • Novartis AG
  • OneOme, LLC
  • Pfizer Inc.
  • Rain Oncology Inc.
  • Relay Therapeutics
  • Sanofi SA
  • Strata Oncology, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Variantyx, Inc.
  • Xilis, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market was valued at USD 2.81 billion in 2025 and is projected to grow to USD 3.00 billion in 2026, with a CAGR of 6.68%, reaching USD 4.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.81 billion
Estimated Year [2026] USD 3.00 billion
Forecast Year [2032] USD 4.42 billion
CAGR (%) 6.68%

A strategic primer introducing how diagnostic innovation, therapeutic evolution, and data integration are jointly redefining precision oncology clinical pathways and commercial approaches

Precision oncology stands at an inflection point as converging advances in therapeutics, diagnostics, and data analytics reshape clinical decision making and commercial strategy. Recent innovations in immunotherapy modalities, targeted agents, and molecular diagnostics have shifted the emphasis from one-size-fits-all approaches to finely stratified patient care pathways, demanding new evidence-generation models and closer alignment across clinical, regulatory, and payer stakeholders.

This introduction synthesizes the principal drivers of change, outlines the practical implications for developers and providers, and frames the subsequent sections that probe structural shifts, tariff-related supply chain risks, and segmentation-specific dynamics. Stakeholders face accelerating complexity: multiplex assays and next-generation sequencing outputs are informing therapy selection in real time, and companion diagnostic pairing is increasingly integral to clinical trial design and product positioning.

Moreover, as care delivery becomes more decentralized, diagnostic laboratories and ambulatory settings are adopting technologies that were once confined to tertiary centers. Transitioning from proof-of-concept to scalable implementation requires integrated operational plans, cross-functional collaboration, and investment in data interoperability. The subsequent analysis highlights where organizational focus is most likely to yield durable clinical and commercial advantage.

How converging therapeutic advances, diagnostic multiplexing, and evolving payer expectations are forcing integrated strategic approaches across oncology development and delivery

The landscape of precision oncology is undergoing transformative shifts driven by technological maturation, regulatory evolution, and changing stakeholder expectations. Immunotherapies such as CAR T-cell interventions and checkpoint inhibitors have moved from novelty to essential components of treatment algorithms, redefining outcomes in hematologic malignancies and selected solid tumors. Concurrently, targeted therapies delivered as monoclonal antibodies or small molecule inhibitors continue to refine therapeutic windows through improved target validation and resistance management strategies.

Diagnostics have evolved from single-analyte tests to multiplexed platforms; immunohistochemistry and fluorescence in situ hybridization remain foundational, while polymerase chain reaction assays and next-generation sequencing now enable broader genomic profiling at clinically actionable depth. This diagnostic breadth supports more precise stratification across common cancer types, allowing clinicians to match interventions to tumor biology with greater confidence.

Commercially, payers and health systems are demanding stronger evidence of clinical utility and real-world benefit, prompting sponsors to design adaptive trial frameworks and post-approval evidence programs. Partnerships between diagnostics providers and pharmaceutical developers are expanding, with co-development and bundled reimbursement models gaining traction. Taken together, these shifts elevate the importance of integrated clinical development strategies that anticipate regulatory expectations and delivery system constraints.

Assessing the operational and strategic consequences of new tariff policies on supply chains, laboratory operations, and clinical program resilience across precision oncology

The introduction of new tariff policies in 2025 has introduced additional layers of operational complexity across the precision oncology ecosystem, affecting supply chains for reagents, instrument components, and biologic production inputs. Manufacturers of monoclonal antibodies, cell-therapy materials, and sequencing platforms face higher landed costs for certain imported raw materials and instrument subassemblies, prompting reassessments of sourcing strategies and inventory practices.

These tariff-related pressures have ripple effects through clinical development and laboratory operations. Diagnostic laboratories reliant on imported consumables may encounter longer procurement lead times and greater cost volatility, which can complicate assay standardization and laboratory accreditation timelines. Clinical trial sponsors operating global studies must now account for variable local costs and potential disruptions to investigational product supply, influencing site selection and trial logistics.

In response, organizations are intensifying efforts to diversify supplier bases, prioritize domestic manufacturing partnerships where feasible, and redesign packaging and shipment practices to reduce exposure to tariff-sensitive categories. Regulatory submissions and quality programs must incorporate contingency planning for supplier substitutions, and contracting teams are negotiating more flexible terms with vendors. While tariffs present material execution risks, they are also accelerating investments in regionalized manufacturing capacity and robust supply network mapping to preserve continuity in both therapeutic and diagnostic delivery.

Segmentation-driven insights that delineate therapeutic categories, cancer types, diagnostic technologies, biomarker classes, and end-user deployment realities to guide prioritization

A careful segmentation-driven lens clarifies where value is created and where operational attention is required. When considering therapy type, hormonal treatments continue to anchor several care pathways, immunotherapies encompass both cellular approaches such as CAR T-cell therapy and systemic checkpoint inhibitors, and targeted therapy spans monoclonal antibodies as well as small molecule inhibitors; each therapeutic category carries distinct development, manufacturing, and commercialization considerations that influence cross-functional planning.

Cancer-type segmentation highlights the divergent clinical and diagnostic needs across disease areas: breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer each present unique biomarker landscapes, differing standard-of-care backdrops, and variable payer willingness to reimburse advanced diagnostics and combination regimens. Tailoring clinical evidence strategies to the natural history and treatment paradigms of each tumor type enhances the relevance of diagnostic-therapeutic pairings.

Technology segmentation separates the methodological approaches that underpin contemporary diagnostics, including fluorescence in situ hybridization, immunohistochemistry, next-generation sequencing, and polymerase chain reaction. Each technology offers trade-offs across sensitivity, throughput, turnaround time, and operational footprint, influencing which settings can realistically adopt them. Biomarker-type segmentation-covering epigenetic testing, genetic testing, and protein testing-further refines where assays will impact treatment decisions and regulatory pathways.

End-user segmentation clarifies deployment and commercialization pathways: ambulatory care centers, clinics, diagnostic laboratories, and hospitals differ in capital capacity, workflow integration capability, and reimbursement coding practices. Aligning product design and service models to the operational realities of these end users supports faster adoption and smoother implementation. Collectively, this layered segmentation approach supports more precise prioritization of investment, evidence generation, and go-to-market sequencing.

Comparative regional analysis highlighting how adoption, reimbursement, and infrastructure differences across major geographies drive differentiated precision oncology strategies

Regional dynamics are shaping both adoption patterns and strategic priorities across the precision oncology ecosystem. In the Americas, innovation hubs and extensive clinical infrastructure support rapid uptake of advanced therapeutics and comprehensive genomic profiling, yet divergent payer environments and reimbursement pathways require targeted evidence planning and payer engagement strategies tailored to national and subnational markets.

Within Europe, the Middle East & Africa, heterogeneous regulatory landscapes and variable access to specialized care influence how diagnostics and novel therapies are introduced. Centralized health technology assessment mechanisms in parts of Europe emphasize comparative effectiveness and cost-effectiveness, while select markets in the Middle East are building capacity for advanced cell therapies and precision diagnostics. In parts of Africa, constrained laboratory infrastructure and supply chain fragility necessitate tailored models for decentralized testing and durable reagent supply.

The Asia-Pacific region presents a spectrum of mature metropolitan centers alongside rapidly developing healthcare systems. High-throughput sequencing adoption and investments in domestic biologics manufacturing are notable in several markets, creating opportunities for regional supply partnerships and localized clinical development. At the same time, regulatory harmonization and variable reimbursement criteria require flexible access strategies that can accelerate patient access while meeting local evidence requirements. Across regions, stakeholders must reconcile global product strategies with nuanced local operational and regulatory realities.

How strategic alliances, platform investments, and vertical integration among leading players are reshaping competitive dynamics and value capture in precision oncology

Leading organizations in therapeutics, diagnostics, and integrated service provision are reshaping competitive dynamics through strategic alliances, platform investments, and vertical integration. Biopharmaceutical sponsors are increasingly collaborating with diagnostic developers to co-design companion assays and parallel evidence-generation programs that support regulatory filings and payer conversations. Diagnostic laboratories and instrument providers are investing in automation and digital reporting to scale high-complexity testing while improving reproducibility and turnaround times.

Supply chain partners and contract manufacturers are expanding capabilities in cell-therapy support services and biologics fill-finish operations to meet rising demand for complex modalities. Technology companies are deploying cloud-based analytics and machine learning to enhance variant interpretation and to create clinician-facing decision support tools that translate sequencing outputs into actionable insights. These moves are influencing strategic partnerships, M&A activity, and the formation of preferred supplier networks.

Across the ecosystem, firms that can demonstrate end-to-end value-linking robust analytical validity, clinical utility, and practical implementation support-are positioned to secure stronger adoption in provider networks and to engage more effectively with payers. Operational excellence in manufacturing, regulatory acumen, and the capacity to deliver real-world evidence will distinguish leaders from followers in the near to medium term.

Practical and high-impact recommendations for leaders to integrate diagnostic-development, supply resilience, and evidence generation to accelerate adoption and payer acceptance

Industry leaders should take decisive steps to align clinical development, diagnostic strategy, and commercial implementation so that therapeutic advances translate into durable patient benefit and sustainable business outcomes. Priorities include embedding companion diagnostic development early in the therapeutic lifecycle to de-risk regulatory pathways and to create clearer value propositions for payers and providers. Leaders should reinforce supply chain resilience through supplier diversification, dual sourcing where feasible, and strategic investments in regional manufacturing capabilities.

Operationally, organizations must invest in interoperable data platforms and evidence-generation frameworks that support rapid accumulation of real-world outcomes. Strengthening collaborations with diagnostic laboratories and care delivery settings will accelerate adoption, particularly when implementation workflows and reimbursement pathways are clearly addressed. In parallel, commercial teams should develop tailored health-economic narratives that reflect the specific clinical contexts of each cancer type and the diagnostic technologies employed.

Finally, fostering cross-functional governance that integrates regulatory, clinical, commercial, and supply chain decision-making will reduce time-to-adoption risks and improve alignment across launch and post-launch activities. By prioritizing these actions, leaders will be better positioned to navigate regulatory complexity, payer scrutiny, and operational disruption while delivering measurable improvements in patient care.

Robust multi-method research methodology combining expert interviews, regulatory and clinical evidence review, and scenario analysis to underpin actionable insights

The research behind this synthesis integrates a multi-method approach to capture technological, clinical, regulatory, and operational developments across precision oncology. Primary interviews with clinical thought leaders, laboratory directors, and supply chain executives provided qualitative insights into the operational realities of assay implementation and therapeutic deployment. These firsthand perspectives were triangulated with public regulatory decisions, peer-reviewed clinical literature, and technical product documentation to ensure alignment with the latest clinical and technological standards.

Secondary analysis of diagnostic workflows, technology adoption case studies, and payer policy statements informed the assessment of deployment constraints and reimbursement drivers. Scenario analysis was applied to stress-test supply chain vulnerabilities and to identify pragmatic mitigation steps that organizations are currently implementing. The methodology emphasizes transparency in source attribution and conservative interpretation of qualitative inputs, focusing on observable trends and documented policy shifts rather than speculative projections.

Throughout the research process, efforts were made to corroborate findings across multiple stakeholders and to surface divergent perspectives where consensus is lacking. This mixed-methods framework is intended to provide decision-makers with a balanced, actionable view of the strategic and operational choices that will shape precision oncology over the near term.

Synthesis of strategic conclusions emphasizing integration of diagnostics, therapy development, and resilient operations to secure durable patient and commercial outcomes

In conclusion, precision oncology is transitioning into an era defined by integrated diagnostics, modality-specific therapeutic strategies, and heightened expectations for real-world evidence. The interplay between immunotherapies, targeted agents, and advanced diagnostic platforms is prompting stakeholders to rethink development paradigms, commercial models, and operational infrastructure. Organizations that synchronize companion diagnostic development with therapeutic programs, build resilient supply networks, and invest in interoperable data systems will be better equipped to translate scientific advances into consistent clinical benefit.

Tariff-related supply risks and varied regional access environments underscore the need for flexible, regionally informed strategies. By prioritizing cross-functional governance and early payer engagement, sponsors and service providers can mitigate adoption barriers and accelerate the translation of innovations into standard practice. The path forward favors those who combine scientific rigor with pragmatic operational design, ensuring that promising therapies reach the right patients efficiently and sustainably.

Taken together, these conclusions provide a strategic foundation for stakeholders seeking to navigate the evolving precision oncology ecosystem with clarity and purpose.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Precision Medicine Market, by Product Type

  • 8.1. Diagnostics
  • 8.2. Therepy
    • 8.2.1. Hormonal Therapy
    • 8.2.2. Cell & Gene Therapy
    • 8.2.3. Immunotherapy
  • 8.3. Inhibitor Drugs
  • 8.4. Monoclonal Antibodies

9. Oncology Precision Medicine Market, by Technology

  • 9.1. FISH
  • 9.2. IHC
  • 9.3. Next Generation Sequencing
  • 9.4. PCR

10. Oncology Precision Medicine Market, by Biomarker Type

  • 10.1. Epigenetic Testing
  • 10.2. Genetic Testing
  • 10.3. Protein Testing

11. Oncology Precision Medicine Market, by Cancer Type

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Lung Cancer
  • 11.4. Melanoma
  • 11.5. Prostate Cancer

12. Oncology Precision Medicine Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Oncology Precision Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oncology Precision Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oncology Precision Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oncology Precision Medicine Market

17. China Oncology Precision Medicine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca PLC
  • 18.7. B. J. Madan & Co.
  • 18.8. Bayer AG
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Cepheid Inc.
  • 18.11. Eli Lilly & Company
  • 18.12. F. Hoffmann-La Roche Ltd
  • 18.13. Genome Medical boasts
  • 18.14. GSK PLC
  • 18.15. IQVIA Inc.
  • 18.16. Laboratory Corporation Of America Holding
  • 18.17. llumina, Inc.
  • 18.18. Merck KGaA
  • 18.19. Novartis AG
  • 18.20. OneOme, LLC
  • 18.21. Pfizer Inc.
  • 18.22. Rain Oncology Inc.
  • 18.23. Relay Therapeutics
  • 18.24. Sanofi S.A.
  • 18.25. Strata Oncology, Inc.
  • 18.26. Takeda Pharmaceutical Company Limited
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Variantyx, Inc.
  • 18.29. Xilis, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THEREPY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)